300mg/m2 IV over 1 hour every 12 on days 1-3 of induction for a total dose of 1.8 g/m2.

375mg/m2 each week x 4 weeks of induction, beginning on day 1

3g/m2 IV over 1 hour every 12 during consolidation for a total of 8 doses

45mg/m2/day IV over 30 minutes on days 1, 2, 3 during consolidation

450mg unlabeled tositumomab over 1 hour, followed by 5 millicurie (mCi) Iodine I-131 labeled tositumomab over 20 minutes on day 0. Therapeutic dose of labeled tositumomab will be administered on day 15.

Percent of subjects who achieved a complete response (CR) or partial response (PR) any time during the treatment period.

CR = complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy.

PR =

1. >/= 50% decrease in sum of the product of the diameters (SPD) of up to six of the largest dominant nodes or nodal masses.
2. No increase should be observed in the size of other nodes, liver, or spleen.
3. Splenic and hepatic nodules must regress by ≥ 50% in their SPD or, for single nodules, in the greatest transverse diameter.
4. Except splenic and hepatic nodules, involvement of other organs is usually assessable and no measurable disease should be present.
5. Patients who achieve a CR by the above criteria, but who have persistent morphologic bone marrow involvement will be considered partial responders.
6. No new sites of disease should be observed.

The number of patients who develop secondary malignancies including solid tumors, acute leukemia and myelodysplasia or other bone marrow failure syndromes.

Disease-free survival is measured from the date of CR or CRu to date of relapse or death

Subjects who achieved a complete response. 9 patients experienced disease progression; 4 patients died.

4 patients were lost-to-follow-up and 11 patients are still living, so DFS was calculated using the last date of follow-up.

Overall Survival is measured from the first day of chemotherapy until death from any cause.

All subjects who received chemotherapy

Percent of subjects who achieved a complete response (CR) or partial response (PR) any time during the treatment period.

CR = complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present before therapy.

PR =

1. >/= 50% decrease in sum of the product of the diameters (SPD) of up to six of the largest dominant nodes or nodal masses.
2. No increase should be observed in the size of other nodes, liver, or spleen.
3. Splenic and hepatic nodules must regress by ≥ 50% in their SPD or, for single nodules, in the greatest transverse diameter.
4. Except splenic and hepatic nodules, involvement of other organs is usually assessable and no measurable disease should be present.
5. Patients who achieve a CR by the above criteria, but who have persistent morphologic bone marrow involvement will be considered partial responders.
6. No new sites of disease should be observed.

The number of patients who develop secondary malignancies including solid tumors, acute leukemia and myelodysplasia or other bone marrow failure syndromes.

All patients who received chemotherapy